vaccin
infecti
bronchiti
chicken
gallu
gallu
domesticu
arguabl
success
certainli
wide
use
vaccin
diseas
caus
coronavirus
other
bovin
canin
felin
porcin
coronavirus
infecti
bronchiti
viru
ibv
togeth
genet
relat
coronavirus
turkey
meleagri
gallopavo
ringneck
pheasant
phasianu
colchicu
group
coronaviru
sever
acut
respiratori
syndrom
sar
coronaviru
tent
group
known
mammalian
coronavirus
group
ibv
replic
respiratori
tissu
includ
nose
trachea
lung
airsac
caus
respiratori
diseas
also
kidney
associ
minor
major
nephriti
oviduct
mani
part
alimentari
tract
oesophagu
proventriculu
duodenum
jejunum
bursa
fabriciu
caecal
tonsil
rectum
cloaca
usual
without
clinic
effect
viru
persist
reexcret
onset
egg
lay
month
age
believ
consequ
stress
come
lay
genet
line
chicken
differ
extent
ibv
caus
mortal
chick
respect
clearanc
viru
acut
phase
live
attenu
passag
chicken
embryon
egg
ibv
strain
introduc
vaccin
follow
coupl
decad
later
inactiv
vaccin
boost
protect
egglay
bird
live
vaccin
usual
appli
meattyp
chicken
day
age
experiment
situat
result
steril
immun
challeng
virul
homolog
viru
although
chicken
may
protect
clinic
sign
loss
ciliari
activ
trachea
sometim
vaccin
chick
may
respond
protect
immun
respons
protect
short
live
start
declin
appar
week
vaccin
vaccin
base
highli
attenu
strain
ibv
exist
score
serotyp
defin
neutral
test
crossprotect
often
poor
consequ
chicken
may
revaccin
anoth
serotyp
two
three
week
later
singl
applic
inactiv
viru
gener
led
protect
chicken
two
applic
led
protect
report
remain
other
practic
field
inactiv
vaccin
use
lay
bird
previous
prime
two
three
live
attenu
viru
vaccin
increas
protect
lay
bird
egg
product
loss
induc
sustain
level
serum
antibodi
pass
progeni
larg
spike
glycoprotein
compris
carboxytermin
subunit
approxim
amino
acid
residu
anchor
viru
envelop
aminotermin
subunit
approxim
residu
believ
larg
form
distal
bulbou
part
subunit
purifi
ibv
viru
express
use
baculoviru
express
bird
fowlpoxviru
vector
induc
viru
neutral
antibodi
although
protect
immun
respons
induc
multipl
inocul
requir
percentag
protect
chicken
low
commerci
applic
remark
express
bird
use
nonpathogen
fowl
adenoviru
vector
induc
protect
chicken
two
experi
differ
littl
sequenc
result
poor
crossprotect
differ
amino
acid
chang
serotyp
suggest
small
number
epitop
immunodomin
respect
neutral
antibodi
initi
studi
role
ibv
nucleocapsid
protein
n
immun
suggest
immun
sever
acut
respiratori
syndrom
sar
emerg
human
guangdong
provinc
china
late
subsequ
spread
contin
earli
follow
year
chanyeung
yu
lee
et
al
peiri
et
al
poutanen
et
al
tsang
et
al
shortli
spread
viru
beyond
china
caus
agent
quickli
identifi
speci
coronaviru
sar
coronaviru
previous
unknown
ksiazek
et
al
marra
et
al
peiri
et
al
rota
et
al
inde
protein
sar
coronaviru
low
amino
acid
ident
known
coronavirus
tent
assign
new
coronaviru
group
three
exist
coronaviru
group
tabl
initi
devis
basi
lack
antigen
relationship
speci
differ
group
pedersen
et
al
et
al
enjuan
et
al
et
al
probabl
vast
major
human
popul
suscept
sar
coronaviru
sar
epidem
contain
case
enorm
effort
sacrific
larg
number
individu
associ
mani
public
author
sever
infect
fulli
suscept
popul
die
doubtless
greater
proport
would
die
medic
attent
focuss
upon
sadli
larg
proport
death
countri
sustain
health
care
worker
addit
human
miseri
dire
econom
consequ
countri
affect
last
sar
case
earli
epidem
june
diseas
might
aris
transmiss
suspect
anim
reservoir
transmiss
human
possibl
asymptomat
carrier
evid
studi
avian
infecti
bronchiti
viru
ibv
felin
coronaviru
coronavirus
establish
persist
infect
chick
experiment
infect
ibv
day
age
reexcret
viru
around
week
age
jone
ambali
suspect
stressor
start
egg
product
caus
releas
viru
approxim
cat
natur
infect
felin
coronaviru
becam
asymptomat
carrier
excret
viru
year
addi
jarrett
addi
et
al
other
excret
viru
period
sever
month
world
health
organis
call
develop
vaccin
sar
short
review
look
experi
ibv
vaccin
half
centuri
might
instruct
regard
develop
sar
vaccin
sar
coronaviru
provision
place
group
base
criteria
previous
use
place
coronavirus
group
ie
extrem
low
amino
acid
ident
protein
three
group
natur
organ
nonstructur
protein
gene
suggest
name
ibv
caus
respiratori
diseas
although
replic
limit
respiratori
tract
major
respiratori
viru
chicken
domest
fowl
endem
probabl
countri
rais
chicken
host
rang
consid
limit
chicken
cavanagh
naqi
although
genet
similar
coronavirus
caus
diseas
turkey
enter
diseas
guy
cavanagh
et
al
pheasant
respiratori
kidney
diseas
lister
et
al
gough
et
al
cavanagh
et
al
ibv
occur
global
chicken
kept
larg
small
scale
wunderwald
hoop
exist
score
serotyp
genotyp
cavanagh
meuleman
et
al
farsang
et
al
problemat
regard
prophylaxi
ibv
caus
decili
ciliat
epithelia
nose
trachea
clinic
sign
similar
common
cold
caus
human
group
group
human
coronavirus
respect
cavanagh
cavanagh
chicken
especi
day
week
age
exhibit
nasal
discharg
snick
similar
sneez
wateri
eye
lethargi
dhinakar
raj
jone
cavanagh
naqi
chicken
exhibit
vibrat
eman
lower
respiratori
tract
small
area
pneumonia
may
observ
lung
dhinakar
raj
jone
notwithstand
fact
titr
viru
lung
similar
nose
trachea
bronchiti
consid
caus
pneumonia
welfar
point
view
hardest
hit
chick
day
week
age
may
die
directli
viral
infect
greater
number
die
follow
secondari
bacteri
infect
overal
slow
growth
caus
econom
loss
juvenil
matur
bird
suffer
less
ibv
infect
although
econom
consequ
infect
egglay
stock
disastr
egg
product
drop
precipit
usual
rise
back
normal
flock
whole
discuss
later
ibv
grow
mani
epitheli
surfac
beyond
respiratori
tract
review
dhinakar
raj
jone
although
mani
alimentari
tract
tissu
suscept
ibv
infect
enter
tissu
usual
manifest
clinic
recent
strain
ibv
associ
diseas
proventricul
cranial
glandular
compart
stomach
adjac
gizzard
caudal
muscular
compart
yu
et
al
nephriti
uncommon
proport
natur
ibvinfect
meattyp
bird
environment
factor
play
role
ibv
strain
intrins
nephropathogen
reproduc
caus
nephriti
inocul
experiment
specif
pathogen
free
chicken
lambrecht
et
al
pensaert
lambrecht
cook
et
al
li
yang
oviduct
also
suscept
ibv
may
contribut
diminish
egg
product
ibv
contain
number
structur
protein
ie
present
viron
group
coronavirus
nucleocapsid
protein
associ
kb
singlestrand
positivesens
rna
genom
larg
spike
glycoprotein
smaller
integr
membran
glycoprotein
molecul
envelop
protein
lai
cavanagh
enjuan
et
al
et
al
contain
haemagglutinin
esteras
glycoprotein
found
group
coronavirus
coronaviru
protein
dimer
trimer
cavanagh
gallagh
buchmeier
lewicki
gallagh
glycopolypeptid
ibv
like
group
coronavirus
cleav
aminotermin
approxim
amino
acid
residu
carboxytermin
approxim
residu
glycopolypeptid
lai
cavanagh
ibv
protein
demonstr
determin
host
cell
rang
vitro
protein
gene
infecti
cdna
clone
beaudett
strain
casai
et
al
replic
mammalian
vero
bhk
cell
replac
strain
replic
cell
line
recombin
viru
unabl
replic
casai
et
al
recombin
replic
primari
chick
kidney
cell
beaudett
strain
whether
protein
ibv
determin
tissu
tropism
vivo
remain
determin
ibv
initi
infect
upper
respiratori
tract
titr
live
viru
maxim
nose
trachea
day
post
inocul
eyedrop
intranas
remain
day
depend
strain
tabl
ambali
jone
hofstad
yoder
thereaft
titr
fall
detect
level
although
viru
still
detect
day
studi
ambali
jone
viru
restrict
ciliat
mucussecret
cell
review
dhinakar
raj
jone
similar
viru
titr
occur
lung
airsac
sometim
peak
littl
nose
trachea
small
area
pneumonia
may
observ
lung
dhinakar
raj
jone
lucio
fabric
investig
growth
sever
isol
ibv
chicken
although
quantifi
viru
recov
show
infecti
viru
recov
trachea
bronchu
lung
oesophagu
proventriculu
duodenum
jejunum
caeca
caecal
tonsil
kidney
cloaca
longest
period
isol
respect
kidney
caecal
tonsil
latter
distal
end
alimentari
tract
bird
ambali
jone
use
anoth
strain
strain
g
ibv
produc
high
titr
kidney
similar
trachea
tabl
variou
alimentari
tract
tissu
proventriculu
duodenum
ileum
caecal
tonsil
bursa
fabriciu
rectum
peak
titr
trachea
kidney
within
amount
tabl
fluoresc
reveal
locat
viru
epitheli
cell
sever
isol
compar
g
strain
isol
much
less
frequent
kidney
rectal
content
elhouadfi
et
al
organ
cultur
studi
show
strain
studi
bhattacharje
jone
grew
proventriculu
bursa
kidney
explant
grow
caecal
tonsil
rectal
explant
experi
hofstad
yoder
titr
kidney
bursa
fabriciu
approxim
two
order
magnitud
lower
respiratori
tissu
number
ibv
strain
low
passag
number
embryo
high
eggpassag
viru
passag
almost
undetect
kidney
bursa
gave
reduc
titr
trachea
lung
intens
studi
tropism
apart
upper
respiratori
tract
kidney
although
small
proport
ibv
isol
exhibit
high
nephropathogen
caus
mortal
within
week
intratrach
inocul
pensaert
lambrecht
absenc
vaccin
histopatholog
immunochem
studi
process
show
strain
viru
attack
mainli
lower
nephron
collect
duct
epitheli
cell
chen
et
al
ultrastructur
investig
reveal
viru
replic
segment
tubul
duct
frequent
epitheli
cell
collect
duct
collect
tubul
distal
convolut
tubul
henl
loop
chen
extent
mortal
age
relat
greatest
chick
lambrecht
et
al
vari
accord
line
bird
exampl
egg
layertyp
bird
meattyp
bird
respect
pensaert
lambrecht
bird
small
lymphoid
organ
harderian
gland
eyesocket
major
contributor
local
produc
antibodi
protect
oculonas
mucosa
review
dhinakar
raj
jone
inocul
mild
vaccin
strain
ibv
eyedrop
result
replic
viru
gland
partial
damag
toro
et
al
increas
number
plasma
cell
enlarg
lymphoid
foci
ibv
also
isol
anoth
lymphoid
organ
bursa
fabriciu
tabl
elhouadfi
et
al
ambali
jone
gross
histopatholog
lesion
occur
even
infect
vaccin
strain
recent
yu
et
al
studi
pathogenesi
three
isol
ibv
proventriculu
chicken
flock
affect
proventriculi
experiment
infect
strain
result
agedepend
mortal
bird
chicken
necropsi
sick
chicken
reveal
mucosa
proventriculu
thicken
exud
milki
fluid
squeez
entir
proventriculu
enlarg
thu
ibv
strain
group
product
infect
larg
rang
epitheli
surfac
liter
top
bottom
chicken
isol
differ
extent
replic
nonrespiratori
tabl
titr
ibv
strain
g
respiratori
nonrespiratori
tissu
follow
intranas
eyedrop
inocul
chick
ambali
jone
viru
titr
log
cd
g
follow
day
inocul
tissu
produc
clinic
diseas
nonrespiratori
tissu
notabl
kidney
proventriculu
pantrop
ibv
might
case
sar
coronaviru
latter
associ
pneumonia
also
diarrhoea
although
remain
demonstr
whether
sar
viru
replic
enter
tissu
peiri
et
al
point
differ
wherea
sar
viru
associ
sever
clinic
sign
respiratori
enter
tract
ibv
usual
limit
diseas
respiratori
tract
appropri
short
review
go
detail
extens
antigen
variat
exhibit
ibv
darbyshir
et
al
ignjatov
mcwater
cook
et
al
cavanagh
meuleman
et
al
farsang
et
al
issu
may
aris
sar
coronaviru
said
amino
acid
differ
protein
two
strain
ibv
suffici
chang
serotyp
larg
spike
glycoprotein
compris
carboxytermin
subunit
approxim
amino
acid
residu
anchor
viru
envelop
aminotermin
subunit
approxim
residu
believ
larg
form
distal
bulbou
part
cavanagh
lai
cavanagh
subunit
induc
virusneutr
vn
antibodi
demonstr
variou
way
failur
induc
vn
viru
remov
induct
vn
antibodi
releas
virion
treatment
urea
nonion
deterg
follow
affin
chromatographi
ignjatov
galli
express
vaccinia
viru
recombin
tomley
et
al
product
monoclon
antibodyresist
mutant
mutat
part
spike
protein
gene
cavanagh
et
al
koch
et
al
kant
et
al
experiment
vaccin
studi
usual
involv
applic
viru
nostril
eyedrop
sometim
direct
applic
trachea
protect
determin
challeng
week
vaccin
challeng
viru
appli
rout
three
main
approach
assess
protect
observ
clinic
sign
commonli
use
remov
trachea
day
challeng
follow
either
quantit
assess
ciliari
activ
detect
live
challeng
viru
usual
inocul
embryon
egg
second
third
method
result
similar
deduct
made
regard
protect
marquardt
et
al
although
studi
challeng
viru
isol
individu
whose
ciliari
activ
unaffect
littl
affect
arguabl
declar
chicken
nonprotect
recoveri
small
amount
challeng
viru
ciliari
activ
normal
stringent
ibv
serotyp
differ
amino
acid
adzhar
et
al
kingham
et
al
although
differ
gelb
et
al
differ
ibv
protein
region
rare
exceed
cavanagh
et
al
cavanagh
et
al
gener
speak
immun
induc
inocul
one
serotyp
protect
poorli
infect
heterolog
serotyp
regard
protect
respiratori
tract
experi
heterolog
challeng
virus
broke
chicken
ie
crossprotect
hofstad
marquardt
et
al
picault
et
al
challeng
virus
known
differ
viru
use
initi
infect
chicken
broke
immun
case
rosenberg
et
al
hofstad
collect
report
show
crossprotect
rang
poor
moder
poor
commerci
purpos
although
case
differ
among
report
may
also
due
differ
stringenc
protect
assess
discuss
later
winterfield
et
al
use
clinic
criteria
assess
crossprotect
vaccin
strain
massachusett
serotyp
conclud
protect
chicken
group
challeng
serotyp
known
differ
protein
protect
assess
less
reisol
challeng
viru
use
criterion
protect
doubt
field
applic
vaccin
homolog
prevail
field
strain
given
better
protect
heterolog
vaccin
crossprotect
nephriti
also
usual
poor
although
strain
crossprotect
other
pensaert
lambrecht
cook
et
al
monoclon
antibodyresist
mutant
investig
reveal
mani
amino
acid
involv
format
vn
epitop
locat
within
first
third
quarter
linear
polypeptid
cavanagh
et
al
koch
et
al
kant
et
al
sequenc
analysi
variant
genet
similar
amino
acid
ident
shown
differ
within
two
region
cavanagh
et
al
adzhar
et
al
moreov
variant
differ
amino
acid
residu
behav
differ
serotyp
cook
cavanagh
et
al
would
small
differ
sar
coronaviru
isol
practic
signific
conceiv
variant
eg
small
differ
sar
coronaviru
field
ie
within
natur
host
case
variant
infect
human
would
variant
abl
break
immun
induc
vaccin
base
strain
isol
human
earli
unfortun
protect
studi
base
close
relat
variant
ibv
cavanagh
et
al
inocul
group
chicken
virul
isol
challeng
isol
differ
amino
acid
differ
serotyp
cook
protect
assess
retent
ciliari
activ
trachea
challeng
two
variant
ident
result
challeng
score
rel
measur
retent
ciliari
activ
virtual
homolog
challeng
challeng
two
other
isol
ident
respect
result
higher
challeng
score
indic
less
crossprotect
although
number
statist
significantli
differ
also
three
experi
one
group
bird
initi
inocul
viru
clearli
protect
homolog
challeng
chicken
individu
inocul
high
dose
log
infecti
viru
primari
inoculum
therefor
lack
protect
bird
unlik
due
failur
initi
infect
primari
viru
rather
heterogen
immun
respons
studi
approxim
chicken
group
inocul
challeng
strain
one
serotyp
fulli
protect
winterfield
et
al
hofstad
picault
et
al
parson
et
al
cavanagh
et
al
cook
et
al
nix
et
al
use
viru
isol
tracheal
ciliari
activ
criterion
result
show
chicken
outbr
although
restrict
set
parent
breed
stock
uniform
respons
ibv
vaccin
one
would
imagin
human
popul
might
even
heterogen
respons
vaccin
sar
nix
et
al
inocul
chicken
sever
virul
isol
greater
amino
acid
ident
assess
serotyp
arkansa
crossreact
vn
test
much
less
other
isol
induc
protect
assess
reisol
challeng
viru
stringent
test
challeng
includ
challeng
strain
lower
serolog
ident
howev
two
isol
induc
crossprotect
chicken
challeng
viru
lower
serolog
ident
clearli
induct
protect
immun
ibv
complex
depend
antigen
related
primari
infect
strain
subsequ
challeng
strain
also
respons
individu
chicken
approxim
chicken
experi
fail
develop
protect
immun
respons
furthermor
breed
chicken
similar
effici
infect
ibv
result
similar
titr
viru
differ
capac
clear
infect
otsuki
et
al
small
differ
amino
acid
would
appear
sometim
respons
poor
crossprotect
born
mind
focu
related
protein
viral
protein
may
role
protect
immun
exampl
nucleocapsid
protein
later
recent
hodgson
r
casai
b
dove
p
britton
cavanagh
manuscript
prepar
substitut
swap
spike
protein
gene
beaudett
infecti
clone
receiv
strain
strain
donor
strain
strain
massachusett
serotyp
amino
acid
ident
beaudett
strain
attenu
pathogen
chicken
respect
chicken
inocul
donor
receiv
spikeswap
recombin
ibv
challeng
receiv
strain
induc
almost
tracheal
protect
assess
ciliari
activ
recombin
ibv
induc
protect
almost
good
donor
strain
due
increas
virul
receiv
strain
spikeswap
recombin
nonpathogen
beaudett
receiv
strain
replic
poorli
receiv
strain
recombin
viru
ident
protein
except
spike
protein
would
appear
poor
immun
induc
receiv
strain
donor
strain
due
amino
acid
differ
differ
residu
support
find
earlier
work
small
differ
contribut
poor
crossprotect
nix
et
al
meattyp
chick
broiler
usual
vaccin
day
hatch
hatcheri
spray
bird
vaccin
earli
age
part
logisticaleconom
reason
also
ibv
endem
everpres
mani
poultryrear
part
world
protect
need
earli
possibl
consequ
ibv
infect
greater
chick
older
bird
also
modern
broiler
goe
process
week
age
vaccin
earli
mani
studi
undertaken
past
year
examin
degre
protect
induc
singl
inocul
variou
serotyp
ibv
mani
studi
refer
previou
section
initi
inocula
virul
strain
attenu
deriv
advantag
degre
protect
immun
induc
viru
part
depend
virul
notwithstand
overal
conclus
reach
alreadi
describ
similar
irrespect
whether
initi
inoculum
viru
virul
attenu
protect
respiratori
tract
follow
singl
live
attenu
viru
vaccin
found
shortliv
gough
alexand
darbyshir
peter
report
declin
number
protect
chicken
week
vaccin
respect
region
given
serotyp
ibv
vaccin
consist
give
accept
protect
field
challeng
bird
might
revaccin
week
first
applic
sometim
vaccin
prepar
sometim
anoth
product
serotyp
sometim
vaccin
heterolog
serotyp
latter
approach
sometim
give
protect
broader
rang
serotyp
cook
et
al
strain
ibv
markedli
nephropathogen
exampl
experiment
tracheal
infect
commerci
meattyp
bird
nephropathogen
strain
result
death
approxim
onethird
group
chicken
within
day
vaccin
coars
spray
homolog
attenu
strain
complet
protect
mortal
upon
challeng
week
later
pensaert
lambrecht
vaccin
nonhomolog
commerci
avail
vaccin
markedli
although
complet
reduc
mortal
homolog
vaccin
prevent
detect
growth
challeng
viru
trachea
ascertain
viru
isol
heterolog
vaccin
challeng
viru
kidney
assess
immunofluoresc
criterion
number
chick
detect
ibv
kidney
reduc
vaccin
homolog
vaccin
heterolog
vaccin
inactiv
oilemuls
ibv
vaccin
develop
object
make
vaccin
would
give
longlast
immun
hen
bird
protect
drop
egg
product
singl
applic
inactiv
viru
induc
littl
protect
egg
loss
mcdougal
box
et
al
muneer
et
al
protect
loss
ciliari
activ
trachea
martin
et
al
howev
immun
chicken
singl
dose
inactiv
ibv
strain
result
depend
criterion
use
develop
respiratori
tract
protect
dose
mg
efficaci
mg
second
experi
base
retent
ciliari
activ
trachea
base
isol
challeng
viru
chicken
protect
dose
mg
third
experi
chicken
judg
protect
retent
ciliari
activ
follow
singl
mg
dose
possibl
larger
amount
viru
use
three
experi
previou
worker
reason
partial
success
part
studi
role
ibv
nucleocapsid
protein
n
protein
protect
immun
discuss
later
boot
et
al
immun
chicken
inactiv
ibv
week
age
week
later
challeng
two
group
chicken
respect
protect
assess
ciliari
activ
trachea
degre
protect
assess
slightli
less
immunofluoresc
use
detect
infect
tracheal
cell
ignjatov
galli
gave
four
dose
mg
inactiv
ibv
bird
develop
protect
assess
nonreisol
challeng
viru
trachea
kidney
respect
three
dose
percentag
increas
four
dose
song
et
al
immun
chicken
three
time
inactiv
nephropathogen
strain
protect
assess
nonreisol
challeng
viru
kidney
trachea
respect
eight
chicken
two
inocul
rise
respect
three
inocul
see
whether
two
dose
inactiv
vaccin
would
protect
loss
egg
product
mcdougal
vaccin
bird
interv
week
challeng
week
later
vaccin
bird
respiratori
sign
last
less
day
compar
day
unvaccin
control
bird
receiv
inactiv
vaccin
larg
protect
drop
egg
product
gough
et
al
demonstr
poor
serum
antibodi
respons
singl
applic
inactiv
infecti
bronchiti
vaccin
titr
increas
markedli
upon
revaccin
week
later
approach
commonli
use
poultri
industri
today
vaccin
young
femal
two
time
live
vaccin
follow
one
dose
inactiv
vaccin
bird
come
lay
live
vaccin
serv
give
protect
young
bird
prime
immun
respons
later
inactiv
vaccin
gough
et
al
box
et
al
finney
et
al
gough
et
al
demonstr
chicken
receiv
one
dose
live
vaccin
follow
inactiv
vaccin
week
later
protect
challeng
week
later
assess
reisol
challeng
viru
trachea
oviduct
kidney
box
elli
report
respons
inactiv
vaccin
poor
given
within
week
live
vaccin
macdonald
et
al
inocul
chicken
ml
convalesc
ibv
serum
two
day
later
challeng
intraven
applic
vaccin
strain
procedur
known
result
nephriti
bird
protect
kidney
diseas
assess
lack
wateri
drop
macroscop
microscop
patholog
kidney
contrast
control
bird
nonimmun
serum
given
passiv
applic
immun
serum
protect
respiratori
infect
although
onset
delay
shorter
durat
variat
among
genet
line
chicken
suscept
ibv
smith
et
al
demonstr
vari
mortal
among
differ
breed
chicken
inocul
mixtur
ibv
isol
alon
conjunct
pool
escherichia
coli
strain
ibv
predispos
bird
infect
bacterium
result
increas
mortal
bumstead
et
al
continu
ibv
coli
infect
show
mark
variat
mortal
among
sever
inbr
line
white
leghorn
chicken
detail
analysi
two
line
line
highli
suscept
line
c
rel
resist
show
rate
viru
product
titr
respiratori
tract
similar
first
day
infect
otsuki
et
al
thereaft
howev
titr
declin
much
slowli
suscept
line
take
twofold
longer
declin
undetect
level
tracheal
explant
two
line
differ
replic
profil
viru
show
differ
bird
intrins
differ
capac
trachea
support
replic
ibv
underli
caus
differ
vivo
might
immunolog
extent
infect
nephropathogen
strain
caus
mortal
also
depend
type
chicken
pensaert
lambrecht
thu
specifi
pathogen
free
flock
die
within
period
day
day
respect
tracheal
inocul
strain
contrast
commerci
meattyp
bird
die
period
humor
immun
respons
ibv
vaccin
mostli
investig
measur
antibodi
level
serum
use
enzymelink
immunosorb
assay
elisa
vn
haemagglutinationinhibit
hai
test
ibv
haemagglutin
poorli
treat
enzym
prepar
contain
neuraminidas
alexand
et
al
schultz
et
al
refer
therein
howev
also
studi
ibv
antibodi
nose
trachea
state
outset
mani
studi
shown
presenc
absenc
titr
serum
antibodi
ibv
correl
protect
vaccin
chicken
may
protect
respiratori
diseas
ibv
irrespect
titr
serum
antibodi
exampl
raggi
lee
ignjatov
galli
profil
serum
antibodi
respons
depend
method
use
detect
follow
infect
chicken
virul
strain
ibv
specif
antibodi
first
detect
elisa
plate
coat
ibv
major
bird
detect
antibodi
day
infect
titr
maxim
within
day
tend
declin
shortli
afterward
mockett
darbyshir
vn
antibodi
delay
comparison
elisadetect
antibodi
first
detect
period
day
infect
peak
within
day
remain
level
remaind
sampl
period
day
inocul
although
bird
vn
antibodi
still
increas
day
sampl
end
hai
antibodi
first
detect
day
peak
day
declin
although
one
bird
hai
titr
peak
much
later
vn
titr
bird
mockett
also
compar
elisa
use
purifi
protein
convent
virusco
elisa
primari
secondari
antibodi
respons
profil
similar
vn
antibodi
later
elisa
antibodi
follow
infect
live
ibv
vaccin
strain
good
primari
immunoglobulin
ig
respons
mockett
cook
martin
et
al
expect
primari
igm
respons
peak
declin
igg
respons
figur
martin
et
al
secondari
igm
respons
ie
respons
second
challeng
infect
peak
time
igg
declin
faster
figur
mockett
cook
suggest
measur
specif
serum
igm
would
use
defin
recent
infect
contrast
respons
ibv
infect
vaccin
inactiv
viru
produc
almost
igm
respons
well
poor
igg
respons
figur
martin
et
al
singl
doubl
vaccin
inactiv
ibv
result
hai
titr
respect
week
respect
vaccin
gough
et
al
singl
inocul
mg
purifi
ibv
induc
maximum
titr
hai
elisa
antibodi
log
log
respect
week
vaccin
vn
antibodi
peak
week
later
log
titr
decreas
eightfold
within
week
peak
holm
measur
vn
antibodi
nasal
wash
challeng
chicken
receiv
either
singl
live
viru
infect
two
intramuscular
inocul
week
apart
inactiv
ibv
serum
antibodi
level
rose
rapidli
group
nasal
antibodi
rose
slowli
group
receiv
inactiv
viru
group
receiv
primari
inoculum
live
viru
doubt
ibv
protein
inocul
induc
protect
immun
proport
chicken
protect
may
depend
manner
protein
present
host
also
evid
n
protein
prime
protect
immun
respons
one
report
n
protein
induc
protect
immun
wherea
singl
inocul
mg
ibv
induc
tracheal
protect
chicken
bird
suscept
immun
ibv
subunit
remov
urea
indic
subunit
requir
induc
protect
immun
releas
treatment
urea
dialys
decreas
concentr
urea
eventu
absenc
urea
might
enabl
renatur
protein
sediment
analysi
indic
expect
releas
urea
monomer
form
longer
multimer
dimer
trimer
molecul
quaternari
structur
notwithstand
chicken
inocul
four
occas
mg
develop
vn
hai
antibodi
respect
posit
follow
three
inocul
protect
immun
assess
experi
ignjatov
galli
dispers
protein
nephropathogen
ibv
use
nonion
deterg
purifi
n
affin
chromatographi
use
monoclon
antibodi
chicken
inocul
four
occas
mg
dose
chicken
immun
n
protein
develop
protect
immun
assess
nonrecoveri
challeng
viru
either
trachea
kidney
follow
challeng
howev
chicken
inocul
develop
tracheal
kidney
immun
four
inocul
respect
percentag
three
inocul
protein
also
express
spodoptera
frugiperda
cell
recombin
autographa
californica
baculoviru
song
et
al
chicken
inocul
cell
contain
express
seven
bird
protect
assess
nonreisol
challeng
nephropathogen
viru
kidney
trachea
respect
protect
rose
respect
eight
chicken
three
inocul
protein
also
express
situ
fowlpoxviru
adenoviru
vector
three
inocul
wing
web
recombin
fowlpoxviru
express
induc
ibvspecif
antibodi
wang
et
al
challeng
ibv
somewhat
less
recoveri
challeng
viru
less
tracheal
damag
control
mild
clinic
sign
greater
protect
achiev
follow
singl
oral
applic
fowl
adenoviru
express
johnson
et
al
protect
assess
nonreisol
challeng
viru
obtain
chicken
two
experi
first
studi
role
ibv
n
protein
immun
boot
et
al
n
protein
form
bacteri
express
fusion
protein
bgalactosidas
initi
experi
mice
inocul
footpad
singl
inocul
result
poplit
lymph
node
cell
prolif
respons
ibv
delayedtyp
hypersensit
respons
obtain
mice
inocul
inactiv
ibv
two
occas
b
inactiv
ibv
follow
n
protein
c
n
protein
follow
inactiv
ibv
experi
subsequ
undertaken
chicken
follow
singl
intramuscular
inocul
inactiv
ibv
bird
protect
respiratori
challeng
assess
ciliari
activ
trachea
none
protect
group
inocul
n
protein
chicken
inocul
either
inactiv
viru
n
protein
inocul
second
time
week
later
inactiv
ibv
challeng
chicken
two
group
respect
develop
protect
immun
tabl
extent
protect
assess
slightli
less
immunofluoresc
use
detect
challeng
viru
tracheal
cell
tabl
third
group
bird
inocul
bgalactosidas
without
n
protein
inocul
inactiv
ibv
chicken
protect
immun
induc
secondari
inocul
inactiv
ibv
tabl
linear
regress
analysi
show
statist
less
group
prime
n
protein
author
conclud
immun
n
protein
induc
protect
immun
activ
cytotox
helper
tcell
respons
two
intramuscular
immun
chicken
plasmid
express
n
protein
fragment
n
protein
induc
immun
respons
protect
bird
infect
ibv
appli
eyedrop
intranas
evidenc
mark
reduct
replic
challeng
viru
seo
et
al
fragment
n
protein
compris
carboxytermin
amino
acid
residu
suffici
induc
protect
yu
et
al
express
fragment
chicken
use
singl
inocul
fowlpoxviru
recombin
upon
challeng
homolog
strain
one
heterolog
strain
ibv
bird
develop
clinic
sign
although
replic
challeng
viru
detect
elisa
bird
protect
challeng
differ
heterolog
strain
collisson
colleagu
seo
collisson
pei
et
al
cytotox
tcell
activ
major
histocompat
complex
restrict
lysi
mediat
cell
adopt
transfer
ibvinfectioninduc
ab
cell
bear
antigen
protect
chick
challeng
infect
review
collisson
et
al
earlier
work
review
dhinakar
raj
jone
tissu
chicken
infect
two
field
strain
ibv
assay
interferon
readili
detect
trachea
lung
low
level
plasma
kidney
liver
spleen
otsuki
et
al
resurg
sar
human
one
would
anticip
author
secondari
immun
inactiv
ibv
chicken
challeng
eyedrop
week
secondari
immun
c
nd
done
would
rapidli
put
oper
variou
surveil
control
measur
prove
success
earli
vaccin
develop
vaccin
might
includ
especi
health
care
worker
contact
wider
commun
coronavirus
establish
persist
infect
least
proport
host
result
chronic
asymptomat
shedder
subsequ
problem
contain
diseas
reason
decis
appli
sar
vaccin
would
taken
lightli
notwithstand
type
vaccin
might
use
poultri
industri
prefer
use
live
vaccin
rather
inactiv
one
former
cheaper
make
buy
easiercheap
appli
financi
consider
would
presum
paramount
case
resurg
sar
human
efficaci
would
import
criterion
use
particular
vaccin
although
also
appli
poultri
industri
cours
safeti
sar
vaccin
might
deem
import
efficaci
assum
vaccin
accept
complet
efficaci
gener
inactiv
vaccin
consid
safer
live
attenu
vaccin
although
safeti
inactiv
vaccin
taken
grant
unless
futur
sar
outbreak
get
rapidli
control
would
seem
unlik
convent
live
attenu
vaccin
would
use
potenti
risk
vaccinerel
problem
reaction
might
deem
high
genet
manipul
addit
tradit
approach
use
mean
attenu
sar
coronaviru
kuo
et
al
thiel
et
al
de
haan
et
al
b
casai
et
al
ortego
et
al
howev
desir
outcom
guarante
fear
vaccinerel
problem
still
harbour
howev
given
almost
total
suscept
global
human
popul
lethal
outcom
case
huge
strain
put
health
care
servic
economi
kill
vaccin
subunit
vaccin
vector
vaccin
might
use
first
instanc
among
select
group
peopl
experi
singl
applic
inactiv
ibv
greatli
promis
context
sar
singl
applic
inactiv
ibv
protect
chicken
sometim
much
less
howev
even
poorli
efficaci
singl
applic
inactiv
sar
vaccin
might
help
reduc
spread
viru
reduc
number
suscept
peopl
first
sign
resurg
sar
author
might
decid
vaccin
key
personnel
view
revaccin
outcom
experi
ibv
regard
promis
number
studi
two
vaccin
inactiv
ibv
produc
protect
immun
chicken
said
studi
even
inocul
high
dose
inactiv
ibv
gave
protect
chicken
might
criterion
protect
use
studi
nonreisol
challeng
viru
might
stringent
amelior
clinic
effect
infect
might
obtain
even
detect
replic
challeng
viru
case
infect
sar
coronaviru
vaccin
protect
worst
outcom
pneumonia
death
might
deem
success
experiment
ibv
subunit
vaccin
form
protein
efficaci
expect
inactiv
viru
two
studi
protect
trachea
achiev
three
vaccin
chicken
respect
protect
kidney
less
effici
respect
vector
sar
vaccin
might
consid
like
less
potenti
problemat
regard
safeti
attenu
sar
coronaviru
perhap
vaccin
might
use
outbreak
develop
epidem
pandem
regard
result
investig
johnson
et
al
promis
singl
oral
applic
nonpathogen
fowl
adenoviru
express
ibv
protein
gave
protect
good
obtain
convent
attenu
ibv
event
type
live
vaccin
use
sar
inactiv
sar
vaccin
might
subsequ
appli
build
upon
initi
vaccin
perhap
provid
least
mediumterm
protect
experi
ibv
good
regard
sar
coronaviru
reemerg
human
protein
might
outbreak
research
ibv
indic
differ
protein
amino
acid
reduc
crossprotect
consequ
differ
among
sar
coronaviru
isol
must
view
complac
find
ibv
n
protein
play
benefici
role
immun
suggest
sar
viru
n
protein
overlook
sar
vaccin
develop
programm
peut
dire
que
le
vaccin
contr
la
bronchit
infectieus
ib
de
poulet
gallu
gallu
domesticu
ont
ceux
qui
parmi
le
vaccin
contr
le
maladi
coronaviru
ont
eu
le
plu
de
et
certain
ceux
qui
ont
le
plu
au
niveau
mondial
le
autr
ceux
coronaviru
bovin
canin
et
porcin
le
viru
de
lib
ibv
le
coronaviru
de
la
dind
meleagridi
gallopavo
et
celui
du
faisan
de
colchid
phasianu
colchicu
avec
lesquel
il
de
relat
font
parti
du
group
de
coronaviru
le
coronaviru
sar
provisoir
dan
le
group
et
le
autr
coronaviru
de
ont
dan
le
group
et
libv
se
multipli
au
niveau
de
tissu
respiratoir
incluant
le
nez
la
le
poumon
le
sac
causant
de
respiratoir
mai
au
niveau
de
rein
une
mineur
ou
majeur
de
loviduct
et
en
endroit
du
tractu
alimentair
oesophag
proventricul
bours
de
fabriciu
amygdal
caecal
rectum
et
cloaqu
san
causer
de
troubl
cliniqu
le
viru
peut
persist
pui
au
de
la
pont
de
moi
passant
pour
une
du
stress
au
moment
de
en
pont
de
de
poulet
libv
notam
en
ce
qui
concern
la
chez
le
poulet
et
la
clearanc
du
viru
la
phase
le
souch
dibv
par
passag
sur
oeuf
ont
comm
vaccin
dan
le
pui
une
vingtain
plu
tard
de
vaccin
ont
pour
booster
la
protect
de
animaux
en
pont
le
vaccin
viru
vivant
sont
dun
jour
chez
le
poulet
de
chair
dan
le
condit
ceci
peut
une
lor
dune
viru
virul
homologu
bien
que
de
poulet
peuvent
contr
le
sign
cliniqu
et
la
pert
de
ciliair
au
niveau
de
la
il
arriv
que
de
poulet
ne
pa
de
immun
protectric
la
protect
par
le
souch
vivant
est
court
ell
commenc
neuf
semain
la
vaccin
pour
le
vaccin
avec
de
souch
libv
de
nombreux
par
la
protect
est
souvent
faibl
en
le
poulet
doivent
avec
le
ou
un
autr
deux
ou
troi
semain
plu
tard
une
simpl
administr
de
vaccin
une
protect
de
sujet
certain
public
deux
administr
de
protect
mai
pour
dautr
la
protect
est
sur
le
terrain
le
vaccin
sont
aux
futur
adult
qui
ont
au
deux
ou
troi
vaccin
viru
vivant
ceci
augment
la
protect
de
animaux
adult
contr
le
pert
de
protect
en
oeuf
et
induit
de
anticorp
un
niveau
soutenu
qui
sont
transmi
la
descend
la
de
spicul
comprend
une
carboxytermin
environ
dacid
qui
permet
lencrag
de
dan
lenvelopp
du
viru
et
une
aminotermin
environ
la
form
bulbeus
important
et
distal
de
la
du
ibv
en
baculoviru
ou
chez
de
oiseaux
ayant
le
vecteur
viral
variol
aviair
induit
de
anticorp
neutralis
vn
de
immun
et
protectric
ont
induit
mai
plusieur
inocul
sont
et
pour
autant
le
pourcentag
de
poulet
est
trop
faibl
b
pour
sur
le
terrain
il
est
soulign
que
lexpress
de
chez
de
oiseaux
administr
dun
vecteur
aviair
non
induit
une
protect
de
et
de
de
poulet
au
cour
de
deux
de
aussi
faibl
que
entr
de
de
peuvent
une
protect
faibl
de
de
au
niveau
de
correspond
ou
acid
peuvent
changer
le
quun
petit
nombr
sont
immunodomin
en
ce
qui
concern
le
anticorp
neutralis
de
sur
le
de
la
de
capsid
n
de
libv
au
niveau
immunitair
ont
que
limmunis
avec
n
en
bien
que
ninduis
pa
direct
une
protect
linduct
de
la
protect
lor
de
linocul
dun
ibv
dan
une
autr
deux
immunis
intramusculair
dun
plasmid
exprim
n
ont
induit
une
protectric
la
base
de
de
libv
nest
pa
encor
parfait
connu
le
taux
danticorp
ne
sont
pa
avec
la
protect
si
le
anticorp
locaux
jouent
un
le
de
transfert
de
cellul
induis
linfect
de
libv
portant
ont
de
poulet
contr
une
virulent
en
conclus
le
vaccin
vivant
de
libv
induis
une
bonn
protect
bien
que
de
court
dune
homologu
si
une
dindividu
ont
de
faibl
le
vaccin
de
libv
sont
insuffisam
efficac
quand
il
sont
une
seul
foi
en
absenc
de
vaccin
viru
vivant
deux
administr
de
vaccin
dibv
sont
beaucoup
plu
efficac
bien
que
cela
ne
soit
pa
une
proposit
valabl
pour
lindustri
avicol
quoi
quil
en
soit
le
et
la
logistiqu
de
ladministr
multipl
de
vaccin
du
sar
devraient
beaucoup
accept
pour
la
protect
de
popul
humain
principal
sil
sagit
de
group
tel
que
le
personnel
soignant
et
le
contact
risqu
ladministr
dun
vaccin
contr
le
sar
est
certain
mieux
si
ell
est
un
petit
nombr
dindividu
qui
pourront
suivi
en
effet
le
personn
peuvent
si
ell
sont
par
le
coronaviru
du
sar
devenir
asymptomatiqu
de
viru
et
ainsi
un
risqu
de
personn
non
pour
lavenir
le
vecteur
aviair
exprim
la
de
libv
qui
une
bonn
permet
optimist
pour
un
vaccin
vivant
contr
le
sar
si
ceci
avec
la
dinclur
le
de
la
n
entwicklung
einer
vakzin
gegen
sar
erfahrungen
mit
der
vakzin
gegen
da
bronchiti
coronaviru
von
den
impfstoffen
gegen
coronavirusinduziert
erkrankungen
sind
wohl
die
impfstoff
gegen
die
se
bronchiti
ib
de
huhn
gallu
gallu
domesticu
die
erfolgreichsten
und
sicherlich
die
eingesetzten
wobei
die
anderen
impfstoff
gegen
rinder
kaninchen
katzenund
schweinecoronaviren
gerichtet
sind
da
ibviru
ibv
ist
zusammen
mit
den
genetisch
verwandten
coronaviren
der
pute
meleagri
gallopavo
und
de
ringfasan
phasianu
colchicu
ein
coronaviru
der
grupp
da
sar
coronaviru
ufig
die
grupp
eingeordnet
wurd
und
die
anderen
bekannten
mammaliercoronaviren
zu
den
gruppen
und
ren
da
ibv
vermehrt
sich
nicht
nur
im
respirationstrakt
nase
trachea
lungen
und
verbunden
mit
verursachung
einer
respiratorischen
erkrankung
sondern
auch
nier
assoziiert
mit
geringbi
hochgradig
nephriti
ovidukt
und
vielen
teilen
de
verdauungstrakt
sophagu
proventriculu
duodenum
jejunum
bursa
fabricii
rektum
und
kloak
dort
jedoch
hnlich
ohn
klinisch
auswirkungen
da
viru
kann
persistieren
und
wird
mit
beginn
der
im
alter
von
monaten
wieder
ausgeschieden
wobei
die
virusaktivierung
al
konsequenz
au
dem
damit
verbundenen
stress
angesehen
wird
verschieden
genetisch
unterscheiden
sich
im
der
durch
ibv
verursachten
sowi
hinsichtlich
der
virusclear
nach
der
akuten
infektionsphas
den
jahren
wurden
durch
passagen
embryonierten
attenuiert
al
lebendvirusvakzinen
hrt
einig
jahrzehnt
folgten
inaktivatvakzinen
zur
boosterung
der
schutzwirkung
bei
legehennen
lebendvirusimpfstoff
werden
hnlich
bei
hnern
ersten
lebenstag
appliziert
unter
experimentellen
bedingungen
kann
die
zu
einer
sterilen
hren
wenn
die
tier
mit
einem
virulenten
homologen
viru
belastungsinfiziert
werden
obwohl
der
tier
tzt
sein
gegen
klinisch
symptom
und
zilienverlust
der
trachea
zeigen
manchmal
der
ken
kein
tzend
immunantwort
die
schutzwirkung
ist
kurzfristig
neun
wochen
nach
der
vakzin
mit
hoch
attenuierten
wird
der
beginn
de
abfal
sichtbar
da
ibv
besitzt
ein
vielzahl
von
serotypen
definiert
durch
neutralisationstest
wobei
die
kreuzschutzwirkung
oft
gere
ist
darau
folgt
dass
hner
zwei
bi
drei
wochen
nach
der
erstvakzin
mit
dem
gleichen
oder
einem
anderen
serotyp
revakziniert
werden
sollten
einmalig
applik
von
inaktiviertem
viru
hat
allgemein
zum
schutz
von
der
hrt
zwei
applikationen
riefen
laut
einig
ffentlichungen
einen
igen
schutz
hervor
anderen
untersuchungen
blieb
er
jedoch
unter
unter
praxisbedingungen
im
feld
werden
inaktivatimpfstoff
bei
legehennen
eingesetzt
die
vorher
zweioder
dreimal
mit
attenuierten
lebendvirusvakzinen
geimpft
worden
sind
die
die
schutzwirkung
bei
den
legehennen
gegen
che
und
induziert
einen
anhaltenden
rperlevel
der
die
nachkommen
weitergegeben
wird
da
spikeprotein
umfasst
ein
karboxyend
die
da
der
verankert
und
ein
aminoend
von
der
angenommen
wird
dass
sie
den
distalen
bulbusteil
de
formt
die
gereinigt
au
dem
ibv
exprimiert
unter
verwendung
von
baculoviru
oder
exprimiert
mit
hilf
ein
induziert
virusneutralisierend
vn
obwohl
ein
immunantwort
induziert
wurd
waren
mehrfach
inokulationen
erforderlich
und
der
prozentsatz
tzter
war
zu
niedrig
r
die
kommerziel
anwendung
bemerkenswerterweis
induziert
die
exprimierung
von
hnern
unter
verwendung
ein
apathogenen
hneradenoviru
zwei
experimenten
ein
schutzwirkung
bei
bzw
der
tier
unterschied
von
wenig
al
den
nnen
geringen
kreuzschutzwirkungen
resultieren
unterschied
im
von
nnen
den
serotyp
vermuten
dass
ein
gering
anzahl
von
epitopen
immunodomin
ist
hinsichtlich
der
neutralisierenden
rper
anfangsuntersuchungen
zur
bedeutung
de
ibvnukleokapsidprotein
n
r
die
legten
nahe
dass
die
immunisierung
mit
bakterien
exprimiertem
n
obwohl
nicht
direkt
schutz
send
die
indukt
der
schutzwirkung
bei
einer
nachfolgenden
inokul
mit
inaktiviertem
ibv
verbessert
einer
anderen
studi
zwei
immunisierungen
mit
einem
n
exprimierenden
plasmid
zu
einer
tzenden
die
grundlagen
der
gegen
ibv
sind
nicht
gut
erforscht
rper
korrelieren
nicht
mit
der
schutzwirkung
doch
lokalen
pern
wird
ein
wichtig
roll
zugesprochen
die
adopt
bertragung
von
durch
ibvinfekt
induzierten
alphabetatzellen
mit
gegen
ein
belastungsinfekt
zusammenfassend
sich
sagen
dass
attenuiert
lebendvirusimpfstoff
einen
guten
aber
kurzfristigen
schutz
gegen
homolog
belastungsinfektionen
hervorrufen
wobei
ein
minderheit
der
tier
ein
schlecht
immunantwort
zeigen
ibvinaktivatvakzinen
sind
nur
wirksam
wenn
sie
nur
einmalig
und
ohn
vorvakzin
mit
einer
lebendvirusvakzin
angewendet
werden
zwei
applikationen
von
inaktiviertem
ibv
sind
viel
effizient
doch
die
ist
ein
kommerziel
nicht
rentabl
vorschlag
die
r
den
schutz
der
menschlichen
lkerung
jedoch
rften
die
kosten
und
die
logistik
ein
mehrfach
applik
einer
sarsinaktivatvakzin
akzeptabl
sein
zumal
wenn
die
anwendung
auf
bestimmt
zielgruppen
wie
ftigt
im
gesundheitswesen
und
hoch
kontaktpersonen
wird
die
applik
ein
sarsimpfstoff
sollt
limitiert
bleiben
auf
ein
minimal
anzahl
von
zielpersonen
die
berwacht
werden
nnen
da
einig
geimpft
individuen
wenn
sie
sich
mit
dem
sarscoronaviru
infizieren
asymptomatisch
virusausscheid
werden
und
somit
ein
risiko
die
nicht
vakziniert
darstellen
beim
blick
auf
die
zukunft
stimmt
die
hohe
wirksamkeit
de
hneradenoviru
optimistisch
r
ein
sarslebendvirusvakzin
mit
der
der
inkorporierung
de
nproteingen
fall
da
r
tig
erachtet
werden
sollt
desarrollo
de
vacuna
frent
al
sar
experiencia
de
la
frent
al
coronaviru
de
la
bronquiti
infecciosa
aviar
la
vacuna
frent
la
bronquiti
infecciosa
ib
de
pollo
gallu
gallu
domesticu
han
sido
la
exitosa
ciertament
la
nment
usada
de
la
vacuna
frent
enfermedad
causada
por
coronaviru
siendo
la
otra
frent
coronaviru
bovino
canino
felino
porcino
el
viru
de
ib
ibv
junto
con
otro
coronaviru
relacionado
como
el
del
pavo
meleagridi
gallopavo
n
phasianu
colchicu
forman
el
grupo
coronaviru
mientra
que
el
coronaviru
del
sar
se
encuentra
en
el
grupo
el
resto
de
coronaviru
de
en
lo
grupo
el
ibv
se
replica
nicament
en
tejido
del
aparato
respiratorio
la
cavidad
nasal
pulmon
saco
causando
enfermedad
respiratoria
sino
en
el
n
asociado
con
nefriti
de
diferent
intensidad
oviducto
en
varia
part
del
tracto
digestivo
fago
duodeno
yeyuno
bolsa
de
fabricio
tonsila
cecal
recto
cloaca
habitualment
sin
efecto
el
viru
pued
persistir
siendo
reexcretado
al
inicio
de
la
puesta
lo
mese
de
edad
probablement
como
consecuencia
del
de
la
entrada
en
puesta
la
diversa
de
pollo
presentan
diferencia
respecto
la
mortalidad
causada
por
la
n
con
ibv
en
pollo
respecto
la
n
del
viru
tra
la
fase
aguda
la
cepa
viva
atenuada
de
ibv
mediant
pase
en
huevo
de
pollo
embrionado
fueron
introducida
como
vacuna
en
un
par
de
fueron
seguida
por
la
vacuna
inactivada
para
prolongar
la
n
en
ave
de
puesta
la
vacuna
viva
se
aplican
normalment
en
ave
de
carn
al
de
edad
en
condicion
experimental
esto
pued
resultar
en
una
inmunidad
cuando
lo
animal
son
desafiado
con
un
viru
logo
aunqu
el
de
lo
pollo
pued
estar
protegido
frent
la
la
de
actividad
ciliar
de
la
en
ocasion
el
de
la
ave
vacunada
responden
con
una
respuesta
inmun
protectora
la
n
suel
durar
poco
empieza
declinar
la
nuev
semana
tra
la
n
con
vacuna
basada
en
cepa
muy
atenuada
existen
vario
serotipo
de
ibv
definido
mediant
de
n
pero
la
cruzada
suel
ser
pobr
en
consecuencia
lo
pollo
son
revacunado
con
el
mismo
u
otro
serotipo
do
tre
semana
la
aplicacion
de
viru
inactivado
normalment
protegen
b
de
lo
pollo
se
ha
descrito
que
do
aplicacion
pueden
llegar
proteg
del
al
de
la
ave
pero
en
otra
ocasion
se
ha
descrito
una
por
debajo
del
en
la
de
campo
la
vacuna
inactivada
se
utilizan
en
ave
de
puesta
que
han
sido
previament
vacunada
con
do
tre
vacuna
de
viru
vivo
atenuado
esto
aumenta
la
n
en
la
ave
de
puesta
frent
la
de
de
huevo
e
induc
una
nivel
de
anticuerpo
sostenido
que
pasa
la
progeni
la
de
la
comprend
una
subunidad
carboxi
termin
de
aproximadament
que
enclava
la
en
el
envoltorio
viral
una
subunidad
aminotermin
de
aproximadament
que
forma
la
part
distal
de
la
part
bulbosa
de
la
la
subunidad
purificada
de
un
viru
de
ibv
expresada
en
baculoviru
en
ave
mediant
un
vector
de
viru
de
viruela
aviar
induc
anticuerpo
neutralizant
vn
aunqu
se
indujeron
respuesta
inmun
protectora
se
requirieron
inoculacion
el
porcentaj
de
pollo
protegido
fue
demasiado
bajo
para
poder
ser
aplicada
comercialment
cabe
remarcar
que
la
n
de
en
ave
mediant
un
vector
de
adenoviru
aviar
indujo
una
de
entr
de
lo
pollo
en
do
experimento
diferencia
de
tan
el
en
la
secuencia
de
la
resultaron
en
una
n
cruzada
baja
diferencia
de
entr
el
el
de
en
la
pueden
cambiar
el
serotipo
lo
que
sugier
que
un
bajo
de
son
inmunodominant
respecto
lo
anticuerpo
neutralizant
lo
estudio
inicial
sobr
el
papel
que
juega
la
de
la
n
de
ibv
en
la
inmunidad
sugieren
que
la
con
n
expresada
en
bacteria
aunqu
induc
directament
la
n
inducida
por
una
n
subsiguient
con
ibv
inactivado
en
otro
estudio
do
inmunizacion
intramuscular
con
un
que
expresaba
n
indujeron
una
inmunidad
protectorala
base
de
la
inmunidad
frent
ibv
totalment
clara
lo
nivel
de
anticuerpo
en
suero
se
correlacionan
con
la
aunqu
se
reconoc
que
lo
anticuerpo
local
juegan
un
papel
important
la
transferencia
de
linfocito
alfabeta
inducido
mediant
una
n
con
ibv
protegieron
lo
pollo
frent
una
n
experiment
en
n
la
vacuna
viva
atenuada
inducen
una
buena
n
aunqu
de
corta
frent
la
experiment
loga
pero
una
de
individuo
pued
respond
pobrement
la
vacuna
de
ibv
inactivada
son
suficientement
eficac
cuando
se
administran
una
vez
se
realiza
una
con
una
vacuna
viva
do
aplicacion
de
una
vacuna
inactivada
de
ibv
son
mucho
eficac
aunqu
parec
una
propuesta
viabl
desd
el
punto
de
vista
comerci
para
la
industria
el
cost
la
de
una
ltipl
de
una
vacuna
inactivada
frent
al
sar
acept
para
la
n
de
una
humana
especialment
si
limitada
grupo
de
alto
riesgo
como
trabajador
relacionado
con
tema
sanitario
persona
con
alto
riesgo
de
contacto
la
de
la
vacuna
frent
al
sar
es
mejor
limitarla
un
mero
de
individuo
de
riesgo
que
puedan
ser
monitorizado
ya
que
alguna
persona
vacunada
al
estar
infectada
con
el
coronaviru
del
sar
volvers
excretor
del
viru
siendo
un
riesgo
para
la
vacunada
de
cara
un
futuro
la
alta
eficacia
de
un
vector
de
adenoviru
aviar
que
expresa
la
subunidad
del
ibv
proporciona
optimismo
con
respecto
una
vacuna
viva
de
sar
si
se
cree
necesario
haber
la
posibilidad
de
incluir
el
gen
de
la
n
